Compare Enveric Biosciences Inc (ENVB) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs KB Financial Group, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.44 (market cap $6.80M), while KB Financial Group, Inc. trades at $122.42 (market cap $42.62B). The key difference: KB Financial Group, Inc. is far larger — about 6267.6× Enveric Biosciences Inc's market cap, and KB Financial Group, Inc. pays a 2.71% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and KB Financial Group, Inc. for 33 Days on average.
| ENVB | KB | |
|---|---|---|
Market Cap | $6.80M | $42.62B |
Volume | 64,867 | 164,291 |
Sector | Health | Financials |
52-Week High | $10.80 | $132.88 |
52-Week Low | $1.27 | $77.50 |
Typical Hold Time | 14 Days | 33 Days |
Enterprise Value | -$1.49M | $215.53T |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
KB Financial Group (KB) trades at $122.00, down 2.19% on the day, with neutral technical signals despite bullish moving averages. The company demonstrates strong fundamental performance with consistent earnings beats, revenue growth from $21.23T in 2025 to $22.37T projected for 2026, and healthy profit margins above 28%. Recent analyst upgrades to Strong Buy highlight momentum potential amid positive South Korean market sentiment.
The stock presents value characteristics with a P/E of 9.68 and P/B below 1.0, supported by robust cash flow generation. However, elevated EV/EBITDA at 21.71 and mixed analyst consensus (33% Buy, 67% Hold) suggest cautious optimism. Key risks include interest rate sensitivity given the banking sector exposure and potential macroeconomic headwinds affecting international operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
